JP2004509900A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004509900A5 JP2004509900A5 JP2002529123A JP2002529123A JP2004509900A5 JP 2004509900 A5 JP2004509900 A5 JP 2004509900A5 JP 2002529123 A JP2002529123 A JP 2002529123A JP 2002529123 A JP2002529123 A JP 2002529123A JP 2004509900 A5 JP2004509900 A5 JP 2004509900A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- compound according
- alkyl
- residue
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 description 34
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 11
- 235000001014 amino acid Nutrition 0.000 description 9
- 150000001413 amino acids Chemical class 0.000 description 9
- 125000000217 alkyl group Chemical group 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 3
- SJZRECIVHVDYJC-UHFFFAOYSA-N 4-hydroxybutyric acid Chemical compound OCCCC(O)=O SJZRECIVHVDYJC-UHFFFAOYSA-N 0.000 description 3
- -1 R is H Chemical group 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Chemical group OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- TVVVGTPTIWIVQS-UHFFFAOYSA-N (11-acetyloxy-4,8-dioxoundecyl) acetate Chemical compound CC(=O)OCCCC(=O)CCCC(=O)CCCOC(C)=O TVVVGTPTIWIVQS-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical group OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- 0 *CCCC(OC(*)N)=O Chemical compound *CCCC(OC(*)N)=O 0.000 description 1
- RFRMMZAKBNXNHE-UHFFFAOYSA-N 6-[4,6-dihydroxy-5-(2-hydroxyethoxy)-2-(hydroxymethyl)oxan-3-yl]oxy-2-(hydroxymethyl)-5-(2-hydroxypropoxy)oxane-3,4-diol Chemical compound CC(O)COC1C(O)C(O)C(CO)OC1OC1C(O)C(OCCO)C(O)OC1CO RFRMMZAKBNXNHE-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical group OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical group C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical group OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Chemical group OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Chemical group CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Chemical group 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Chemical group OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 150000002016 disaccharides Chemical group 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 150000002194 fatty esters Chemical class 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical group OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical group 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 235000002374 tyrosine Nutrition 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23472000P | 2000-09-22 | 2000-09-22 | |
| PCT/US2001/029569 WO2002024715A2 (en) | 2000-09-22 | 2001-09-21 | Gamma-hydroxybutyrate compositions containing carbohydrate, lipid or amino acid carriers |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012196299A Division JP2012246312A (ja) | 2000-09-22 | 2012-09-06 | 炭水化物、脂質、またはアミノ酸キャリアを含むγ−ヒドロキシブチレート組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004509900A JP2004509900A (ja) | 2004-04-02 |
| JP2004509900A5 true JP2004509900A5 (https=) | 2008-11-06 |
Family
ID=22882520
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002529123A Pending JP2004509900A (ja) | 2000-09-22 | 2001-09-21 | 炭水化物、脂質、またはアミノ酸キャリアを含むγ−ヒドロキシブチレート組成物 |
| JP2012196299A Pending JP2012246312A (ja) | 2000-09-22 | 2012-09-06 | 炭水化物、脂質、またはアミノ酸キャリアを含むγ−ヒドロキシブチレート組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012196299A Pending JP2012246312A (ja) | 2000-09-22 | 2012-09-06 | 炭水化物、脂質、またはアミノ酸キャリアを含むγ−ヒドロキシブチレート組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US7015200B2 (https=) |
| EP (1) | EP1325014B1 (https=) |
| JP (2) | JP2004509900A (https=) |
| AU (1) | AU2001291173A1 (https=) |
| CA (1) | CA2423358C (https=) |
| ES (1) | ES2383673T3 (https=) |
| WO (1) | WO2002024715A2 (https=) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9925087B2 (en) | 2000-09-15 | 2018-03-27 | Bruder Healthcare Company, Llc | Wound and therapy compress and dressing |
| US10105259B2 (en) | 2000-09-15 | 2018-10-23 | Bruder Healthcare Company, Llc | Wound and therapy compress and dressing |
| AU2001292683A1 (en) | 2000-09-15 | 2002-03-26 | Bruder Healthcare Company | Wound and therapy compress and dressing |
| ES2383673T3 (es) | 2000-09-22 | 2012-06-25 | Jpi Commercial, Llc | Composiciones de gamma-hidroxibutirato que contienen portadores de hidrato de carbonos |
| US8110209B2 (en) * | 2002-12-20 | 2012-02-07 | Xeris Pharmaceuticals Inc. | Intracutaneous injection |
| CN1747737A (zh) * | 2003-01-13 | 2006-03-15 | 新河药品股份有限公司 | 糖偶联物防止管制药物的滥用 |
| US8133881B2 (en) | 2003-01-13 | 2012-03-13 | Shire Llc | Carbohydrate conjugates to prevent abuse of controlled substances |
| KR20070100686A (ko) * | 2004-09-07 | 2007-10-11 | 오르펀 메디칼, 인크. | 개선된 ｇｈｂ 조성물 |
| US8193211B2 (en) * | 2004-09-30 | 2012-06-05 | Supernus Pharmaceuticals, Inc. | Controlled release compositions of gamma-hydroxybutyrate |
| MX2007005679A (es) * | 2004-11-10 | 2007-07-11 | Univ Columbia | Metodo para tratamiento de desordenes de movimiento. |
| US20120142618A1 (en) * | 2007-02-13 | 2012-06-07 | Btg International Limited | Ketogenic saccharides |
| US8771735B2 (en) * | 2008-11-04 | 2014-07-08 | Jazz Pharmaceuticals, Inc. | Immediate release dosage forms of sodium oxybate |
| US8778398B2 (en) * | 2008-11-04 | 2014-07-15 | Jazz Pharmaceuticals, Inc. | Immediate release formulations and dosage forms of gamma-hydroxybutyrate |
| CA2759251C (en) | 2009-04-23 | 2017-01-03 | Concert Pharmaceuticals, Inc. | 4-hydroxybutyric acid analogs |
| MX391660B (es) | 2010-03-24 | 2025-03-21 | Jazz Pharmaceuticals Inc | Formas de dosis de liberacion controlada para substancias de farmaco de alta dosis, solubles en agua e higroscopicas |
| ES2804540T3 (es) | 2011-02-14 | 2021-02-08 | Concert Pharmaceuticals Inc | Análogos deuterados de ácido 4hidroxibutírico |
| US20160068463A1 (en) | 2012-11-14 | 2016-03-10 | Metabolix, Inc. | Production of salts of 4-hydroxybutyrate using biobased raw materials |
| US8591922B1 (en) | 2012-12-14 | 2013-11-26 | Jazz Pharmacuticals, Inc. | Gamma-hydroxybutyrate compositions and their use for the treatment of disorders |
| US9050302B2 (en) | 2013-03-01 | 2015-06-09 | Jazz Pharmaceuticals Ireland Limited | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
| WO2014143139A1 (en) | 2013-03-15 | 2014-09-18 | Bruder Healthcare Company | Wound and therapy compress and dressing |
| US10398662B1 (en) | 2015-02-18 | 2019-09-03 | Jazz Pharma Ireland Limited | GHB formulation and method for its manufacture |
| CN113061089A (zh) | 2015-09-23 | 2021-07-02 | 凯瑞康宁生物工程（武汉）有限公司 | γ-羟基丁酸的前药及其组合物和用途 |
| US12011388B2 (en) | 2016-03-01 | 2024-06-18 | The Hilsinger Company Parent, Llc | Therapeutic thermal compress with phase-change material |
| US12156831B2 (en) | 2016-03-01 | 2024-12-03 | The Hilsinger Company Parent, Llc | Therapeutic eye compress system |
| US12029681B2 (en) | 2016-03-01 | 2024-07-09 | The Hilsinger Company Parent, Llc | Therapeutic eye mask system |
| US12186296B1 (en) | 2016-07-22 | 2025-01-07 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| UY37341A (es) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada |
| US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12478604B1 (en) | 2016-07-22 | 2025-11-25 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11000498B2 (en) | 2016-07-22 | 2021-05-11 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| USD871598S1 (en) | 2016-11-30 | 2019-12-31 | Bruder Healthcare Company, Llc | Therapeutic eye mask |
| USD844795S1 (en) | 2016-11-30 | 2019-04-02 | Bruder Healthcare Company, Llc | Therapeutic eye mask |
| US20180263936A1 (en) | 2017-03-17 | 2018-09-20 | Jazz Pharmaceuticals Ireland Limited | Gamma-hydroxybutyrate compositions and their use for the treatment of disorders |
| US20200114015A1 (en) * | 2017-04-11 | 2020-04-16 | John K. Thottathil | Novel Alpha-Hydroxy Carboxylic Acid And Derivatives And Other GRAS- Based Prodrugs Of Gamma-Hydroxybutyrate (GHB) And Uses Thereof |
| EP3737353A1 (en) | 2017-12-18 | 2020-11-18 | Tris Pharma, Inc. | Ghb pharmaceutical compositions comprising a floating interpenetrating polymer network forming system |
| WO2019126216A1 (en) | 2017-12-18 | 2019-06-27 | Tris Phama, Inc. | Pharmaceutical compositions comprising a floating interpenetrating polymer network forming system |
| US11337919B2 (en) | 2017-12-18 | 2022-05-24 | Tris Pharma, Inc. | Modified release drug powder composition comprising gastro-retentive RAFT forming systems having trigger pulse drug release |
| WO2019126214A1 (en) | 2017-12-18 | 2019-06-27 | Tris Pharma, Inc. | Pharmaceutical composition comprising ghb gastro-retentive raft forming systems having trigger pulse drug release |
| BR112021006027A2 (pt) | 2018-11-19 | 2021-06-29 | Jazz Pharmaceuticals Ireland Limited | formulações de fármaco resistente a álcool |
| CN113473980A (zh) | 2019-03-01 | 2021-10-01 | 弗拉梅尔爱尔兰有限公司 | 在进食状态下具有改善的药代动力学的γ-羟基丁酸酯组合物 |
| US20210186907A1 (en) | 2019-12-24 | 2021-06-24 | Jazz Pharmaceuticals Ireland Limited | Ghb dosing |
| TW202139986A (zh) | 2020-02-21 | 2021-11-01 | 愛爾蘭商爵士製藥愛爾蘭有限責任公司 | 治療原發性嗜睡症之方法 |
| AU2021292406B2 (en) | 2020-06-18 | 2024-03-14 | XWPharma Ltd. | Controlled release granulations of water-soluble active pharmaceutical ingredients |
| CN116261451A (zh) | 2020-07-24 | 2023-06-13 | 凯瑞康宁生物工程有限公司 | γ-羟基丁酸衍生物的药物组合物和药物动力学 |
| KR20230058151A (ko) | 2020-10-05 | 2023-05-02 | 엑스더블유파마 리미티드 | 감마-하이드록시부티르산 유도체의 변형된 방출 조성물 |
| US12582622B2 (en) | 2020-10-08 | 2026-03-24 | Jazz Pharmaceuticals Ireland Limited | Sodium oxybate to treat idiopathic hypersomnia |
| WO2022082105A2 (en) | 2020-10-16 | 2022-04-21 | Jazz Pharmaceuticals Ireland Limited | Treatment methods using ghb |
| EP4588471A3 (en) | 2021-03-19 | 2025-09-24 | XWPharma Ltd. | Pharmacokinetics of combined release formulations of a gamma-hydroxybutyric acid derivative |
| EP4415701A1 (en) | 2021-10-11 | 2024-08-21 | Jazz Pharmaceuticals Ireland Limited | Method of administering oxybate |
| WO2023135150A1 (en) | 2022-01-11 | 2023-07-20 | Jazz Pharmaceuticals Ireland Limited | Method of administering oxybate |
| US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
| US20230338543A1 (en) * | 2022-04-21 | 2023-10-26 | Zevra Therapeutics, Inc. | Gamma-hydroxybutyrate delivering compounds and processes for making and using them |
| WO2024163966A1 (en) | 2023-02-03 | 2024-08-08 | Tris Pharma, Inc. | Low sodium oxybate once nightly composition |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2226398A1 (de) * | 1972-05-31 | 1973-12-13 | Boehringer Sohn Ingelheim | Neue herzglykoside und verfahren zu ihrer herstellung |
| DE2702687A1 (de) * | 1977-01-24 | 1978-07-27 | Boehringer Sohn Ingelheim | Neue herzglykosidderivate und verfahren zu ihrer herstellung |
| JPS60168044A (ja) * | 1984-02-10 | 1985-08-31 | Sharp Corp | 感湿素子 |
| US5223263A (en) | 1988-07-07 | 1993-06-29 | Vical, Inc. | Liponucleotide-containing liposomes |
| GB8508508D0 (en) * | 1985-04-01 | 1985-05-09 | Creighton A M | Pharmaceutical compositions |
| US4738985A (en) * | 1986-03-19 | 1988-04-19 | The University Of Toronto Innovations Foundations | Pharmaceutical composition and treatment |
| IT1238344B (it) * | 1989-10-20 | 1993-07-13 | Sigma Tau Ind Farmaceuti | Estere della l-carnitina con l'acido gamma-idrossibutirrico e composizioni farmaceutiche che lo contengono per l'inibizione della degenerazione neuronale e nel trattamento del coma |
| IT1240760B (it) | 1990-02-12 | 1993-12-17 | Sigma Tau Ind Farmaceuti | Esteri di acil-l-carnitine con l'acido gamma-idrossibutirrico e composizioni farmaceutiche che li contengono per l'inibizione della degenerazione neuronale e nel trattamento del coma. |
| DE4026265A1 (de) | 1990-08-20 | 1992-02-27 | Boehringer Mannheim Gmbh | Neue phospholipid-derivate von nucleosiden, deren herstellung sowie deren verwendung als antivirale arzneimittel |
| DE4113984C2 (de) | 1991-04-29 | 2002-05-08 | Koehler Chemie Dr Franz | Salze der 4-Hydroxy-Buttersäure |
| GB9112212D0 (en) | 1991-06-06 | 1991-07-24 | Gregoriadis Gregory | Pharmaceutical compositions |
| IT1261485B (it) | 1993-06-24 | 1996-05-23 | Sigma Tau Ind Farmaceuti | Uso di acil l-carnitine gamma-idrossibutirrato per il trattamento di tossicodipendenze. |
| JP2746079B2 (ja) * | 1993-09-07 | 1998-04-28 | 正和薬品株式会社 | 血糖上昇抑制剤および脂質代謝改善剤 |
| SE502990C2 (sv) * | 1993-11-22 | 1996-03-04 | Perstorp Ab | Användning av en inositoltrisfosfatester för beredning av ett smärtstillande läkemedel |
| SE503122C2 (sv) * | 1993-11-22 | 1996-03-25 | Perstorp Ab | Användning av en inositoltrisfosfatester för behandling av inflammatoriska tillstånd |
| SE502989C2 (sv) * | 1993-11-22 | 1996-03-04 | Perstorp Ab | Användning av en inositoltrisfosfatester för beredning av läkemedel |
| CN1315473C (zh) * | 1997-03-17 | 2007-05-16 | 英国技术集团国际有限公司 | 治疗组合物 |
| US5990162A (en) | 1997-08-29 | 1999-11-23 | Orphan Medical, Inc. | Method for treatment of fibromyalgia and chronic fatigue syndrome |
| US6623730B1 (en) * | 1999-09-14 | 2003-09-23 | Tepha, Inc. | Therapeutic uses of polymers and oligomers comprising gamma-hydroxybutyrate |
| ES2383673T3 (es) * | 2000-09-22 | 2012-06-25 | Jpi Commercial, Llc | Composiciones de gamma-hidroxibutirato que contienen portadores de hidrato de carbonos |
| US7686215B2 (en) | 2005-05-21 | 2010-03-30 | Apple Inc. | Techniques and systems for supporting podcasting |
| US9405855B2 (en) | 2014-03-27 | 2016-08-02 | Sap Ag | Processing diff-queries on property graphs |
-
2001
- 2001-09-21 ES ES01971269T patent/ES2383673T3/es not_active Expired - Lifetime
- 2001-09-21 WO PCT/US2001/029569 patent/WO2002024715A2/en not_active Ceased
- 2001-09-21 JP JP2002529123A patent/JP2004509900A/ja active Pending
- 2001-09-21 AU AU2001291173A patent/AU2001291173A1/en not_active Abandoned
- 2001-09-21 CA CA2423358A patent/CA2423358C/en not_active Expired - Fee Related
- 2001-09-21 US US10/381,224 patent/US7015200B2/en not_active Expired - Lifetime
- 2001-09-21 EP EP01971269A patent/EP1325014B1/en not_active Expired - Lifetime
-
2005
- 2005-07-18 US US11/183,482 patent/US7572605B2/en not_active Expired - Lifetime
-
2009
- 2009-05-13 US US12/465,069 patent/US8778301B2/en not_active Expired - Fee Related
-
2012
- 2012-09-06 JP JP2012196299A patent/JP2012246312A/ja active Pending
-
2013
- 2013-05-20 US US13/897,748 patent/US20130324759A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004509900A5 (https=) | ||
| CA2423358A1 (en) | Gamma-hydroxybutyrate compositions containing carbohydrate, lipid or amino acid carriers | |
| JP2002517491A5 (https=) | ||
| KR970042553A (ko) | 캠프토테신 유도체 | |
| JPH1129497A5 (https=) | ||
| JP2002525329A5 (https=) | ||
| JP2020063241A5 (https=) | ||
| CN110418639B (zh) | 肾上腺素前药的舌下或口含给药制剂 | |
| RU2003104808A (ru) | Жидкий состав метформина | |
| HUE027395T2 (hu) | Eszközök nyálkahártyán keresztül történõ bejuttatására, javított felszívódással | |
| CA2341568A1 (en) | Stabilized pharmaceutical composition in lyophilized form | |
| JP2008505902A5 (https=) | ||
| KR20010090602A (ko) | 디디에스 화합물 및 그의 측정방법 | |
| JP2004010479A (ja) | ブロック共重合体とアンスラサイクリン系抗癌剤を含む新規固型製剤及びその製造法 | |
| BRPI0921705B1 (pt) | composição farmacêutica antimicrobiana e seu uso | |
| US20030166513A1 (en) | Dds compound and process for the preparation thereof | |
| WO2015173427A2 (fr) | Composition a action rapide d'insuline comprenant un compose anionique substitue et un compose polyanionique | |
| CN109328058A (zh) | 口腔粘膜贴附材料及其制造方法 | |
| JP2002509154A5 (https=) | ||
| JP2005187328A (ja) | イブプロフェン含有解熱鎮痛組成物、及び感冒薬 | |
| JPH08295637A (ja) | 口腔部局所投与剤 | |
| CN109771395B (zh) | 一种含有槲皮素的口腔黏膜剂及其制备方法 | |
| WO2002083154A1 (en) | Use of cationic dextran derivatives for protecting dose-limiting organs | |
| JP2006052172A5 (https=) | ||
| WO2007147373B1 (en) | Pharmaceutical composition for injectional, particularly targeted local administration |